Author's response to reviews

Title: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Authors:

Mélodie Dell'Ova (Melodie.DellOva@chu-fortdefrance.fr)
Eléonora De Maio (DeMaio.Eleonora@iuct-oncopole.fr)
Séverine Guiu (s/guiu@cgfl.fr)
Lise Roca (Lise.Roca@icm.unicancer.fr)
Florence Dalenc (dalenc.florence@iuct-oncopole.fr)
Anna Durigova (Anna.DurigovaAbdouh@hcuge.ch)
Frédéric Pinguet (Frederic.Pinguet@icm.unicancer.fr)
Khedidja Bekhtari (khedidja.Bekhtari@icm.unicancer.fr)
William Jacot (William.jacot@icm.unicancer.fr)
Stéphane Pouderoux (stephane.pouderoux@icm.unicancer.fr)

Version: 3 Date: 12 March 2015

Author's response to reviews: see over
Author's covering letter for initial submission

Title: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Authors:

Version: 1 Date: 14 February 2015

Comments: see over
Montpellier, February 13, 2015

To the attention of the BMC Cancer Editor-in-Chief

Dear Editor-in-Cief,

Please find attached our manuscript entitled "Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study" which we would like to submit for consideration for publication as an Original Article in BMC Cancer.

In this article we report the efficacy and safety profile of eribulin mesylate for the treatment of heavily pretreated metastatic breast cancer patients. This is to date the largest clinical series in a clinical practice setting and our results comfort the use of this new molecule and pledge for the evaluation of the eribulin mesylate - trastuzumab combination in this setting. In addition, we report for the first time putative predictive and prognostic factors, as tumour biology, primary taxanes sensitivity and metastatic sites could represent useful predictive and prognostic factors under eribulin mesylate treatment.

Considering the clinical implications of these results in heavily pretreated metastatic breast cancer patients, and, to date, the lack of defined predictive and prognostic factors, we decided to submit our manuscript to BMC Cancer.

The manuscript has not been submitted, neither is under consideration in any other journal.

Sincerely yours,
William Jacot, MD, PhD, on behalf of all the authors.